Mayne Pharma recipient of $4.8m Federal Government Grant
9 May 2022
Mayne Pharma Group Limited is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful.
Non Executive Director appointment
22 Mar 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ann Custin has accepted an invitation to join the Board of Mayne Pharma, effective 23 March 2022.
Mayne Pharma 2022 Half Year Results Media Release
25 Feb 2022
Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS.
Mayne Pharma expands US dermatology portfolio
10 Feb 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States.
Non Executive Director appointment and retirement
17 Jan 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Kathryn MacFarlane, PharmD, has accepted an invitation to join the Board of Mayne Pharma, effective 1 February 2022.
Mayne Pharma adds a generic PROTOPIC® to US portfolio
12 Jan 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of tacrolimus ointment, 0.1% in the United States
TGA approval of novel oral contraceptive NEXTSTELLIS®
29 Nov 2021
Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets).
2021 AGM Chairman’s Address
23 Nov 2021
Welcome everyone, I'm Frank Condella, the Chair of Mayne Pharma. It is a pleasure to welcome you to Mayne Pharma’s 2021 Annual General Meeting. As we have a quorum present, I am delighted to open the meeting
2021 AGM CEO’s Speech
23 Nov 2021
Today I will provide you with an update on the launch of NEXTSTELLIS our novel contraceptive which received FDA approval earlier this year together with some comments around our evolving specialty products business model and our outlook.